Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: PET/CT

Abdominal Imaging

Volumn 35, Issue 2, 2010, Pages 232-240

  Tateishi, Ukihide ^a   Terauchi, Takashi ^b   Inoue, Tomio ^a   Tobinai, Kensei ^c  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Malignant lymphoma; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM 67;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; LYMPHOMA; MEDICAL DECISION MAKING; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY;

CONTRAST MEDIA; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; PELVIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROPERITONEAL SPACE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953476240     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-009-9516-9     Document Type: Review

References (35)

1. Jhanwar YS, Straus DJ (2006) The role of PET in lymphoma. J Nucl Med 47:1326-1334
2. Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro- D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066-1074
3. Hicks RJ, Mac Manus MP, Seymour JF (2005) Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35:165-175
4. Podoloff DA, Macapinlac HA (2007) PET and PET/CT in management of the lymphomas. Radiol Clin North Am 45:689-696
5. Kumar R, Maillard I, Schuster SJ, Alavi A (2004) Utility of fluo-rodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 42:1083-1100
6. Burton C, Ell P, Linch D (2004) The role of PET imaging in lymphoma. Br J Haematol 126:772-784
7. Ulaner GA, Colletti PM, Conti PS (2008) B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy\initial experience. Radiology 246:895-902
8. Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59
9. Beal KP, Yeung HW, Yahalom J (2005) FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 16:473-480
10. Karam M, Novak L, Cyriac J, et al. (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175-183
11. Kumar R, Xiu Y, Zhuang HM, Alavi A (2006) 18F-fluorodeox-yglucose- positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol 155:357-363
12. Tsai EY, Taur A, Espinosa L, et al. (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142:577-584
13. Wohrer S, Jaeger U, Kletter K, et al. (2006) 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 17:780-784
14. Ghersin E, Keidar Z, Eldad DJ, et al. (2007) Multimodality imaging of direct ureteric involvement in non-Hodgkin's lymphoma using PET/CT, CT urography and antegrade CT pyelography. Br J Radiol 80:e283-e286
15. Abouzied MM, Crawford ES, Nabi HA (2005) 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 33:145-155
16. Vesselle HJ, Miraldi FD (1998) FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 18:805-823
17. von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405-422
18. Allen-Auerbach M, Quon A, Weber WA, et al. (2004) Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lym-phoma. Mol Imaging Biol 6:411-416
19. Freudenberg LS, Antoch G, Schutt P, et al. (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31:325-329
20. Raanani P, Shasha Y, Perry C, et al. (2006) Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 17:117-122
21. Morimoto T, Tateishi U, Maeda T, et al. (2007) Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement. Eur J Radiol 67:508-513
22. Vera P, Ouvrier MJ, Hapdey S, et al. (2007) Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging 34:1943-1952
23. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. (2006) PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47:1643-1648
24. Even-Sapir E, Lievshitz G, Perry C, et al. (2007) Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease. Radiol Clin North Am 45:697-709
25. Bar-Shalom R (2007) Normal and abnormal patterns of 18F- fluorodeoxyglucose PET/CT in lymphoma. Radiol Clin North Am 45:677-688
26. Perry C, Herishanu Y, Metzer U, et al. (2007) Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 79:205-209
27. Macapinlac HA (2004) The utility of 2-deoxy-2-[18F]fluoro-D-glucose- positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol 6:200-207
28. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL (2005) Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 237:1038-1045
29. Schaefer NG, Taverna C, Strobel K, et al. (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy\is biopsy of FDG-avid lesions still needed? Radiology 244:257-262
30. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. (2006) Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma. Curr Probl Diagn Radiol 35:151-163
31. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23:1409-1415
32. Cook GJR, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron emission tomography scanning: potential for error in interpretation. Semin Nucl Med 7:441-446
33. Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, et al. (2006) Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 135:293-302
34. la Fougere C, Hundt W, Brockel N, et al. (2006) Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 33:1417-1425
35. Rhodes MM, Delbeke D, Whitlock JA, et al. (2006) Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 28:300-306